PharmExec Blog

PharmExec’s Top Tweets

Greetings to the Biotech/Pharma twittersphere!

Starting this week, we’ll be compiling top tweets about the industry (semi-)regularly in this blog.

Please help with suggestions on what you think should make the list. Tweet @PharmExecutive or email cmcdonald@advanstar.com. Read More »

Posted in social media, Strategy | Tagged , , | Leave a comment

Key 2015 Obamacare Actions that U.S. Rx Manufacturers Should Be Considering

At first glance Obamacare developments for the American Rx industry in 2015 appear fairly benign. However, digging deeper suggests that each, in its own way, could cause various actions with potential for substantial uncertainty for the U.S. pharmaceutical industry next year. If your response to this profound observation was, “Really, what’s new?” — read on. Read More »

Posted in healthcare, Op-Ed, Strategy | Tagged , | 1 Comment

Pharma in Argentina: An Interview with Juan Pablo Bagó

2014 marked the 80th anniversary of Laboratorios Bagó, a market leader in Argentina and also  Latin America, with products in  in 47 countries. In this interview with Pharmaboardroom.com, Juan Pablo Bagó, general director of pharma in Argentina for the Bagó group, discusses the state of R&D in Argentina, and explains why his group is planning for a 75 percent of turnover from international markets in the coming years.Juan-Pablo-Bagó

http://pharmaboardroom.com/interviews/bago-group-juan-pablo-bago-general-director-pharma-argentina/

Posted in Emerging Markets, Global, R&D, Strategy | Tagged , , , , | Leave a comment

Indonesia “Most Promising” Emerging Market in 2015

Indonesia is expected to be the most promising market for pharma next year, thanks to its new healthcare insurance scheme Jaminan Kesehatan Nasional (JKN), according to Reenita Das, partner and senior vice president of Healthcare & Life Sciences at Frost & Sullivan.Jakarta-Indonesia Read More »

Posted in Emerging Markets, Global, Op-Ed | Tagged , , , , , | Leave a comment

Spending Rises on Prescription Drugs, Despite Overall Slowdown in Healthcare Outlays

More new medicines came to market in 2013, and fewer blockbuster drugs lost patent protection, trends that federal analysts say led to more rapid growth in outlays for prescription drugs in 2013. Retail prescription drug spending rose 2.5% to reach $271 billion a year ago, much faster than the low growth rate of 0.5% in 2013, according to the annual report on national health spending from the Centers for Medicare & Medicaid Services (CMS), published by Health Affairs. Read More »

Posted in drug spending, healthcare, IP, pricing | Tagged , , | 1 Comment
  • Categories

  • Meta